REGN
REGENERON RECEIVES FAST TRACK DESIGNATION FROM U.S. FOOD AND DRUG ADMINISTRATION FOR ASPECT OF AXOKINE(R) OBESITY DEVELOPMENT PROGRAM
Tuesday, January 21, 2003 BiopharmaWatch Research 1 min read Key Takeaway: REGENERON RECEIVES FAST TRACK DESIGNATION FROM U.S. FOOD AND DRUG ADMINISTRATION FOR ASPECT OF AXOKINE(R) OBESITY DEVELOPMENT PROGRAM
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema
Full Press Release Details
REGENERON RECEIVES FAST TRACK DESIGNATION FROM U.S. FOOD AND DRUG ADMINISTRATION FOR ASPECT OF AXOKINE(R) OBESITY DEVELOPMENT PROGRAM.